0
0
The U.S. Food and Drug Administration (FDA) has approved Modeyso, a new drug developed by Jazz Pharmaceuticals, for the treatment of diffuse midline glioma (DMG), a rare and aggressive brain tumor that primarily affects children and young adults. This tumor arises in midline structures of the brain and spinal cord, including the brainstem, thalamus, and spinal cord. Modeyso is the first systemic therapy approved by the FDA specifically for DMG characterized by a particular mutation that has not responded to previous treatments.
The approval is based on data from 50 patients enrolled in five clinical trials, showing that Modeyso reduced tumor size in about 22% of patients, with those responding achieving a median benefit duration of just over 10 months. The drug will be available in the U.S. shortly as an oral capsule taken once a week.
Jazz Pharmaceuticals acquired Modeyso through its $935 million acquisition of biotech company Chimerix earlier this year. The acquisition marked a strategic move for Jazz to deepen its oncology portfolio beyond its existing treatments for blood and lung cancers. The CEO of Jazz Pharmaceuticals highlighted that the drug addresses a significant unmet medical need for patients suffering from this devastating tumor.
Diffuse midline glioma is difficult to treat due to its location around critical brain areas that are unsafe to operate on, and patients often face a prognosis of less than a year to live after diagnosis. About 3,940 people in the U.S. currently live with this type of tumor, according to the National Institutes of Health.
Jazz Pharmaceuticals stated its commitment to working closely with healthcare professionals and patient advocates to ensure Modeyso’s swift availability to patients. This FDA approval marks a meaningful advancement in treatment options for a condition with very limited therapies.
Disclaimer: This article is based on information available as of August 6, 2025, from public sources including Reuters and press releases from Jazz Pharmaceuticals. The efficacy and safety of Modeyso should be discussed with a healthcare professional. The FDA approval is specific to the diffuse midline glioma mutation indicated, and patient outcomes may vary. Readers should not consider this article as medical advice.
